Big Money Sentiment Indicator of Cara Therapeutics Inc (NASDAQ:CARA) Increases in 2018 Q2 to 1.39

Cara Therapeutics, Inc. (NASDAQ:CARA) Corporate Logo

“Big money” Positions

“Big money sentiment for Cara Therapeutics Inc (NASDAQ:CARA) in Q2 2018 increased to 1.39, according to filings. So its up 0.56, from 2018Q1’s 0.83. 53 hedge funds increased or opened new holdings, while 38 reduced and sold their equity positions in Cara Therapeutics Inc so the sentiment has increased. Funds own 16.95 million shares, up from 15.62 million shares in 2018Q1. Funds holding Cara Therapeutics Inc in top 10 changed to 1 from 1 for the same number . In total 14 funds closed positions, 24 reduced and 28 increased. Also 25 funds bought new Cara Therapeutics Inc stakes.

Most Cara Therapeutics Inc Investors

Rho Capital Partners Inc owns 3.57 million shares in Cara Therapeutics Inc as of Q2 2018. Cara Therapeutics Inc’s shareholder Cypress Capital Management Llc (Wy) owns 74,445 shares as of Q2 2018. In addition, Dafna Capital Management Llc reported 62,811 shares in Cara Therapeutics Inc equivalent to 0.56% of its US long equity exposure. Disciplined Growth Investors Inc Mn revealed 858,287 shares position in Cara Therapeutics Inc. The Virgin Islands – British-based fund Shanda Asset Management Holdings Ltd holds 54,984 shares or 0.16% of their US long equity exposure.

Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities designed to alleviate pain and pruritus by selectively targeting kappa opioid receptors in the United States.The company has $633.91 million market cap. It is developing product candidates that target the body's peripheral nervous system.Last it reported negative earnings. The companyÂ’s lead product candidate comprises I.V.

CARA hit $16.07 during the last trading session after $1.03 change.Cara Therapeutics, Inc. is uptrending after having risen 52.64% since December 8, 2017. CARA has 1.20M volume or 94.85% up from normal. CARA outperformed the S&P 500 by 37.02%.

Cara Therapeutics, Inc. (NASDAQ:CARA) is expected to report earnings on March, 21., according to Faxor. The earnings per share diference is $0.14 or 32.56 % down from last years number. Previous year: $-0.43; Analysts forcast: $-0.57. After $-0.51 earnings per share was revealed last quarter, analysts now see negative EPS growth of 11.76 % for Cara Therapeutics, Inc..

Sei Invs reported 0% of its capital in Cara Therapeutics, Inc. (NASDAQ:CARA). Quantitative Invest Mngmt Ltd Liability invested in 0.01% or 37,200 shs. Legal General Group Inc Public Ltd Co has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Wells Fargo And Communication Mn has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). California Employees Retirement System owns 93,200 shs or 0% of their US capital. Proshare Advisors, Maryland-based fund reported 17,313 shs. 49,225 are held by Art Llc. Susquehanna Interest Group Llp, Pennsylvania-based fund reported 177,544 shs. Raymond James & holds 0% or 13,069 shs in its capital. Citigroup reported 0% of its capital in Cara Therapeutics, Inc. (NASDAQ:CARA). Winslow Evans & Crocker Inc reported 0.04% of its capital in Cara Therapeutics, Inc. (NASDAQ:CARA). Royal Comml Bank Of Canada has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Us State Bank De accumulated 500 shs or 0% of the stock. Ameritas Invest Inc has invested 0% in Cara Therapeutics, Inc. (NASDAQ:CARA). Moreover, Vanguard Grp Inc Inc has 0% invested in Cara Therapeutics, Inc. (NASDAQ:CARA) for 1.25M shs.

Cara Therapeutics, Inc. registered $2.81 million net activity with 0 buys and 12 selling transactions since July 2, 2018. $475,800 worth of Cara Therapeutics, Inc. (NASDAQ:CARA) was sold by CHALMERS DEREK T on Monday, October 1. Another trade for 11,442 shs valued at $230,347 was sold by Stauffer Joseph William. $323,888 worth of stock was sold by Mohindru Mani on Wednesday, October 17.

Cara Therapeutics, Inc. (NASDAQ:CARA) Ratings Coverage

A total of 4 analysts rate Cara Therapeutics (NASDAQ:CARA) as follows: 4 “Buy”, 0 “Hold” and 0 “Sell”. Тherefore 100% are bullish. (NASDAQ:CARA) has 5 ratings reports on 8 Dec 2018 according to StockzIntelligence. In Wednesday, August 8 report Stifel Nicolaus maintained the stock with “Buy” rating. On Friday, June 29 the stock of Cara Therapeutics, Inc. (NASDAQ:CARA) has “Buy” rating given by Canaccord Genuity. On Wednesday, August 15 the stock of Cara Therapeutics, Inc. (NASDAQ:CARA) earned “Buy” rating by Canaccord Genuity.

For more Cara Therapeutics, Inc. (NASDAQ:CARA) news posted recently go to:,,, or The titles are as follows: “Cara Therapeutics: Scratching An Itch Left Unscratched – Seeking Alpha” posted on June 27, 2018, “Here’s Why Cara Therapeutics Jumped 56.5% in the First Half of 2018 – The Motley Fool” on July 15, 2018, “Where Will Cara Therapeutics, Inc. Be in 5 Years? – Nasdaq” with a publish date: June 07, 2018, “Forget Cara Therapeutics’ Earnings — Here’s the Real News – Motley Fool” and the last “12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure – Benzinga” with publication date: November 16, 2018.

Cara Therapeutics, Inc. (NASDAQ:CARA) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.